MD Anderson Cancer Center — Clinical Trial Site

168 Registered trials

71 Currently recruiting

Organisation

MD Anderson Cancer Center

Location

Madrid, Spain

Identifier

ORG-100043950

Address

Calle De Arturo Soria Nº 270, 28033, Spain

Departments

-
#7004: Hematología
#93158011: Oncología
#98358011: Oncology
1308: Hematología y Oncología
172408: Hematología
201: Oncología
724001: Oncología
724002:Oncología
724004: Oncología
804: Ensayos Clínicos, Planta 1ª
Breast Cancer Unit
Cancer Center
Cirugía
Department of Oncology
ES011A: Oncología
Haematology
Hematologia
Hematology
Hematology Department
Jefe de Servicio de Hematologia y Hemoterapia
Medical Oncology
Medical Oncology Department
N/A
Oncología
Oncología Médica
oncologia-hematologia
Oncology
Oncology Department
Oncology Physician
Oncology Service
Radiation Oncology
Research Facility
Servicio de Hematología
Servicio de Oncologia
Servicio de Oncología Medica
Unidad de ensayos clínicos
Unidad de Ensayos Clínicos-Oncología
Urology

Clinical trials at this site (168)

Search interface

Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung Cancer Ended

2022-503071-28-00 Squamous Non-small cell Lung Cancer 5 2023-08-31
A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV … Ended

2022-502620-49-00 Resected Melanoma Stage III or Stage IV 2 2023-08-01
OMX-0407 Phase I Study Ended

2024-514554-75-00 Previously treated unresectable solid tumours 1 2023-03-16
A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended

2023-504111-33-00 Platinum-resistant High-grade Serous Ovarian, Primary P 4 2023-02-14
Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat… Ended

2024-514714-12-00 Metastatic Pancreatic Ductal Adenocarcinoma 10 2022-11-11
Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors Ended

2024-514357-29-00 Advanced solid tumors 1 2022-11-04
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended

2024-513992-42-00 venous thromboembolism (VTE) in patients with gastroint 10 2022-09-13
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on… Ended

2023-509569-19-00 venous thromboembolism (VTE) 10 2022-08-10
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancer Ended

2024-512639-58-00 Solid Tumors 7 2022-05-07
A study to compare Onivyde manufactured at two different production sites in adult participants with advanced cancer in the pancreas Ended

2024-516760-28-00 Metastatic Pancreatic Adenocarcinoma 2 2022-05-04
"OPAL Master Protocol Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of T… Ended

2023-505097-16-00 Ovarian Neoplasms 4 2022-04-04
GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended

2024-510722-10-00 Malignant Solid Tumors 7 2021-12-13
Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies Ended

2022-500868-36-00 Squamous Cell Carcinoma of Head and Neck 1 2021-08-11
A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cel… Ended

2023-509155-14-00 Peripheral T-cell Lymphoma 4 2021-06-10
A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended

2023-509513-36-00 Melanoma (Stage III and IV) 4 2021-03-24
Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Ended

2024-513313-13-00 Acute Myelogenous Leukemia (AML) or higher-risk Myelody 9 2020-12-09
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Metastatic Castration-Resistant Prostate Cancer 5 2019-08-23
This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa… Ended

2022-502747-35-00 Newly diagnosed advanced (FIGO stage III-IV) high grade 5 2019-02-18
A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in… Ended

2024-512158-12-00 Bladder Cancer Muscle-Invasive Bladder Cancer 5 2018-12-14
Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER… Ended

2024-514999-41-00 HER2 negative metastatic breast cancer (MBC) with nervo 4 2017-04-28
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar… Ended

2023-508010-42-00 Homologous recombination deficiency advanced ovarian ca 5 2016-09-14
A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Ended

2022-501474-19-00 Non-Small Cell Lung Cancer 7
Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended

2023-510361-97-00 Newly Diagnosed RARA-positive Adult Patients with Highe 5